Faes Farma, S.a. · BME:FAE
Faes Farma — 9M 2026 Earnings Presentation
18 slides from Faes Farma's earnings presentation, October 2026
Slide 1: 9M 2026 Results
af FAES FARMA 9M 2026 RESULTS FAES FARMA
Slide 2: Table of Contents
Table of Contents 1/ 2/ 3/ Highlights and main Business performance Results key figures 9M 2026
Slide 3: Highlights and main key figures
1/ Highlights and main key figures
Slide 4: Highlights for the first 9 months of 2026
HIGHLIGHTS AND KEY FIGURES Highlights for the first 9 months of 2026 Total revenue +24%, growth driven mainly by the integration of acquisitions and the strong performance of international direct markets. Business Pharma revenue +24%, with the integration of ophthalmology as a key area. Bilastine wa
Slide 5: Key figures for 9M 2026
HIGHLIGHTS AND KEY FIGURES Key figures for 9M 2026 Revenue PBT 563.5 M€ 87.3 M€ 24% +1% EBITDA Net Profit 124.4 M€ 74.3 M€ 17% 1% 5
Slide 6: Business performance 9M 2026
2/ Business performance 9M 2026
Slide 7: Revenue by portfolio segment
BUSINESS PERFORMANCE 9M 2026 Revenue by portfolio segment Millions of € Millions of euros 9M 2026 9M 2025 % Bilastine Pharmaceuticals 486.5 392.7 24% Bilastine is experiencing the expected impact in Japan associated with the expiry Top 3 pharmaceutical of the molecule’s patent protection. Momentum i
Slide 8: Revenue by business area
BUSINESS PERFORMANCE 9M 2026 Revenue by business area Millions of euros 9M 2026 9M 2025 % Pharmaceuticals 486.5 392.7 24% Animal Nutrition and Health Pharma Iberia 186.6 170.1 10% 12% Iberia Pharma Pharma International (without licences) 216.6 123.4 76% 34% Pharma Licences Pharma Licences 83.3 99.2
Slide 9: Pharma Iberia
BUSINESS PERFORMANCE 9M 2026 Pharma Iberia Revenue 9M 2026 SPAIN -1% €186.6 million 10% The prescription business remains stable, supported by the strong performance of calcifediol and the respiratory product range, offsetting a more challenging environment for bilastine. Spain Portugal 133.3 131.7
Slide 10: Pharma International
BUSINESS PERFORMANCE 9M 2026 Pharma International Revenue 9M 2026 LATAM 18% €216.6 million 76% Latin America continues to perform strongly, reaffirming its growth momentum. Most markets are recording very significant growth: Colombia (+14%), Ecuador (+15%), Peru (+13%) and Central America (+21%), wi
Slide 11: Pharma Licences
BUSINESS PERFORMANCE 9M 2026 Pharma Licences Revenue 9M 2026 BILASTINE LICENCE -23% €83.3 million -16% Bilastine has been affected by the expected launch of generics in Japan. The licence’s performance in other regions remains positive, with solid results in Europe – particularly in Bilastine licenc
Slide 12: Farm Faes
BUSINESS PERFORMANCE 9M 2026 Farm Faes Revenue 9M 2026 €68.6 million 18% FARM Faes 68.6 58.3 Solid business performance, driven primarily by the consolidation of ISF as the main growth driver, increased activity with major clients, an improved product mix and 9M 2025 9M 2026 operational efficiency.
Slide 13: Results 9M 2026
af FAES FARMA Results 9M 2026
Slide 14: Income statement for 9M 2026
9M 2026 RESULTS Income statement for 9M 2026 thousands of € 9M 2026 9M 2025 Change REVENUE Net revenue 551,942 440,953 25% Revenue growth is driven by the new perimeter, strong international growth, and Other operating income 11,602 13,046 -11% Farm Faes's solid performance, which offset the lower c
Slide 15: We reaffirm our 2026 guidance following a strong performance over the first nine months
We reaffirm our 2026 guidance following a strong performance over the first nine months 2026 REVENUE EBITDA 2026* NET DEBT 2026 +17% / +19% +28% / +31% < 2x EBITDA vs 627 M€, 2025 vs 118 M€, 2025 Key growth drivers for 2026 ∕ Driving growth in strategic international markets, particularly Latin Amer
Slide 16: Faes Farma
af FAES FARMA
Slide 17: Legal Disclaimer
LEGAL DISCLAIMER This presentation has been prepared and published by the Faes Farma Group and is provided solely for information purposes. This presentation is not a prospectus and does not constitute an offer or recommendation to invest. This presentation does not constitute a commitment to subscr
Slide 18: Appendix: Breakdown of revenue
€M 9M 2026 9M 2025 Var % Appendix Iberia 186.6 170.1 10% Pharma Spain 131.7 133.3 -1% Prescription 87.2 87.9 -1% 12.6 14.7 -15% Breakdown of revenue* Bilastine RX Calcifediol 32.3 31.3 3% Mesalazine 5.1 5.1 -2% Other 37.3 36.7 2% Healthcare & Consumer 44.4 45.3 -2% Portugal Pharma 55.0 36.8 49% Faes